RYBREVANT FASPRO
LaunchBsAbBLASINGLE-USEVIAL
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYBREVANT FASPRO is a bispecific antibody (amivantamab) combined with hyaluronidase for subcutaneous administration, designed to treat metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. It works by simultaneously blocking EGFR and MET signaling, degrading these receptors on tumor cells, and recruiting immune effector cells (ADCC and trogocytosis) to destroy cancer cells. The hyaluronidase component enables rapid subcutaneous delivery by temporarily increasing tissue permeability.
Launch
Early-stage launch with moderate competitive pressure (30/100); substantial opportunity to establish market position in EGFR-mutant NSCLC segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining the RYBREVANT FASPRO team at launch offers exposure to building a new product franchise in oncology, with responsibility for establishing clinical adoption among pulmonologists and medical oncologists managing EGFR-mutant NSCLC. This is a high-visibility, high-impact career opportunity with the potential to shape the competitive position of a differentiated bispecific modality early in its commercial lifecycle.
Brand Manager
Worked on RYBREVANT FASPRO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.